As a valued Relias Media subscriber, you can find the latest issue of your publication online. The articles below provide timely strategies and research for healthcare providers:
Mild traumatic brain injuries (mTBIs) may lead to adverse cognitive and neuropsychiatric outcomes. The pathways that lead to adverse cognitive outcomes remain to be scientifically elucidated. A prospective cohort study of 656 participants enrolled in the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) study found that at one year, 13.5% of participants with mTBI had poor cognitive outcome compared to 4.5% of controls, highlighting the need for better understanding of the mechanisms leading to poor cognitive and functional outcomes after mTBIs and interventions to optimize cognitive recovery.
This retrospective cohort study compared the effect of amantadine on levodopa-induced dyskinesia (LID) onset with use of anticholinergics and monoamine oxidase type B inhibitors in patients with Parkinson’s disease. The authors concluded that early treatment with amantadine may delay LID onset more than treatment with other symptomatic agents.
Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system caused by the reactivation of the JC virus. The authors of this study conducted a multi-centered retrospective observational study on 64 patients with PML who were treated with recombinant human IL-7 (RhIL-7). Overall, the one-year all-cause survival following start of RhIL-7 was 55% and similar among human immunodeficiency virus/acquired immunodeficiency syndrome, hematological malignancies, and primary immunodeficiencies.
In retrospective studies of patients with generalized myasthenia gravis, those who are refractory to multiple treatments have disease onset at an earlier age, are more likely to have thymic pathology, and are more likely to be double-seronegative (neither acetylcholine receptor nor muscle-specific receptor tyrosine kinase antibodies).
In individuals with subjective cognitive decline, multiple biomarkers of neurodegeneration were found to add predictive values beyond amyloid and tau biomarkers; however, the various neurodegeneration biomarkers were not equivalent and should not be used interchangeably.
Financial Disclosure: None of the authors or planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
